Investment Analysts’ Weekly Ratings Changes for Lantheus (LNTH)

Lantheus (NASDAQ: LNTH) recently received a number of ratings updates from brokerages and research firms:

• 7/29/2026 – Lantheus had its “buy” rating reaffirmed by B. Riley Financial, Inc..
• 7/29/2026 – Lantheus had its price target lowered by Mizuho from $120.00 to $115.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – Lantheus was downgraded by Brookline Capital Markets from “strong-buy” to “hold”.
• 7/16/2026 – Lantheus had its price target raised by Truist Financial Corporation from $115.00 to $125.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Lantheus had its price target raised by Mizuho from $115.00 to $120.00. They now have a “market outperform” rating on the stock.
• 7/9/2026 – Lantheus had its price target raised by B. Riley Financial, Inc. from $97.00 to $129.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Lantheus had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $115.00 price target on the stock.

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.